Robert Drolet, PhD, is a principal scientist at Merck. He joined the company in 2009 and has worked on small molecule drug discovery for Alzheimer’s and Parkinson's disease indications as well as fluid and imaging-based biomarker discovery and development. He is currently the pre-clinical program and translational biomarker program lead in neurodegenerative diseases.
Dr. Drolet obtained his doctorate from Michigan State University, conducting neuroscience graduate research in the laboratory of Dr. John Goudreau. He completed postdoctoral training in neuroscience at the Pittsburgh Institute for Neurological Disorders under the supervision of Dr. Timothy Greenamyre, where he discovered pathological similarities between autonomic and enteric nervous system dysfunction in Parkinson’s and the rotenone pre-clinical model of the disorder.